Long-term course of interferon-treated chronic hepatitis C

Cammà, Calogero; Marco, Vito Di; Iacono, Oreste Lo; Almasio, Piero Luigi; Giunta, Marco; Fuschi, Patrizia; Vaccaro, Alessandra; Fabiano, Carmelo; Magrin, S.; Stefano, R. Di; Bonura, Celestino; Pagliaro, Luigi; Craxı̀, Antonio

doi:10.1016/s0168-8278(98)80274-2

Cited by 79 publications

(64 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[28][29][30][31][32][33][34] The present study, which was conducted in Caucasian patients, confirmed the original observations from Japan, describing a double-peaked incidence of recurrence after HCC resection, 7 and demonstrated the efficacy of IFN only on the late peaks occurring more than 2 years after tumor resection. It has been shown that in patients with cirrhosis, despite the extremely low chances of HCV clearance as those reported herein (only 7% of sustained virological response), the reduction in inflammation and progression of fibrosis produced by IFN could lead to carcinogenesis inhibition and reduction in the incidence of new tumor foci at a late interval after HCC removal or ablation.…”

Section: Intention-to-treat Analysis Of Rfs (Primary End Point) Andsupporting

confidence: 89%

“…Clinical research in the context of prevention of HCC recurrence after tumor removal or ablation has been difficult [28][29][30][31] with only 3 RCTs, all from the Asian experience and with no firm conclusions. The present RCT, which was based on a sample size of 150 patients, matching the cumulative population of all previous trials, allows insights into the heterogeneous population of HCV patients with HCC, introducing a subset of patients (pure Fig.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

et al. 2006

View full text Add to dashboard Cite

. The primary end point was recurrence-free survival (RFS); secondary end points were disease-specific and overall survival. Intention-to-treat and subgroup analysis on adherent patients were conducted. Treatment effects on early/late recurrences were assessed using multiple Cox regression analysis. No patient experienced life-threatening adverse events. There were 28 adherent patients (37%). After 45 months of median follow-up, overall survival was 58.5%, and no significant difference in RFS was detectable between the two study arms (24.3% vs. 5.8%; P ‫؍‬ .49). HCC recurred in 100 patients (48 IFN-treated, 52 controls), with a 50% reduction in late recurrence rate in the treatment arm. HCC multiplicity and vascular invasion were significantly related to recurrence (P ‫؍‬ .01 and .0003). After viral status stratification, while no treatment effect was apparent in the mixed HCV؉HBV population and on early recurrences (72 events), there was a significant benefit on late recurrences (28 events) in HCV-pure patients adherent to treatment (HR: 0.3; 95% CI: 0.09-0.9; P ‫؍‬ .04). In conclusion, IFN does not affect overall prevention of HCC recurrence after resection, but it may reduce late recurrence in HCV-pure patients receiving effective treatment. (HEPATOLOGY 2006;44:1543-1554

show abstract

Section: Intention-to-treat Analysis Of Rfs (Primary End Point) Andsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Several studies performed in patients with chronic hepatitis C have suggested that successful antiviral treatment could result in a dramatic decrease in severe clinical events and mortality, life expectancy of patients with SVR being close to general population [6,9,10,24,25] . However, those studies used only interferon-α.…”

Section: Discussionmentioning

confidence: 99%

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

Braks

Ganne‐Carrié²,

Fontaine³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To assess the long-term clinical benefit of sustained virological response (SVR) in patients with hepatitis C virus (HCV) cirrhosis treated by antiviral therapy using mostly ribavirin plus interferon either standard or pegylated. METHODS:One hundred and thirteen patients with uncomplicated HCV biopsy-proven cirrhosis, treated by at least one course of antiviral treatment ≥ 3 mo and followed ≥ 30 mo were included. The occurrence of clinical events [hepatocellular carcinoma (HCC), decompensation and death] was compared in SVR and non SVR patients. RESULTS:Seventy eight patients received bitherapy and 63 had repeat treatments. SVR was achieved in 37 patients (33%). During a mean follow-up of 7.7 years, clinical events occurred more frequently in non SVR than in SVR patients, with a significant difference for HCC (24/76 vs 1/37, P = 0.01). No SVR patient died while 20/76 non-SVR did (P = 0.002), mainly in relation to HCC (45%). CONCLUSION:In patients with HCV-related cirrhosis, SVR is associated with a significant decrease in the incidence of HCC and mortality during a follow-up period of 7.7 years. This result is a strong argument to perform and repeat antiviral treatments in patients with compensated cirrhosis.

show abstract

“…In 1995, a small randomized controlled trial (RCT) of IFN treatment showed a decrease in the incidence of HCC in patients with hepatitis C virus (HCV) cirrhosis compared with that in untreated controls [25]. Following this study, several others, including controlled trials [26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42], have been performed, mostly in patients with HCV infection. Other retrospective cohort studies of a relatively small size have shown a marked degree of heterogeneity, making it difficult to assess the actual level of benefit obtained by IFN treatment.…”

Section: Lessons From Primary Prevention Of Hcc By Ifnmentioning

confidence: 99%

Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma

Kudo¹

2008

Oncology

View full text Add to dashboard Cite

Primary and secondary prevention of hepatocellular carcinoma (HCC) which has become endemic worldwide in recent years are the most important issues in reducing mortality of HCC patients. Among several compounds previously reported for secondary prevention, treatment with interferon (IFN) is widely applied and shows encouraging results. To date, there have been 8 published randomized control trials (RCTs) and 6 published non-RCTs on IFN therapy after curative treatment of HCCs. Positive results were shown in 6 of 8 RCTs and in all of 6 non-RCT cohort studies regarding either recurrence rate or patient survival. The impact of IFN therapy after curative treatment of HCC can be summarized as follows: (1) HCC incidence of recurrence is reduced through viral clearance or long-term IFN treatment, even though HCV is not cleared. (2) Low-dose, long-term IFN (maintenance) therapy may suppress HCC recurrence through direct action of IFN on tumor cells. (3) Patient survival is improved through growth inhibition of recurrent tumors, as well as preservation of liver function. (4) According to the above 3 points, there is more chance to receive curative treatment in the IFN than the non-IFN group. (5) Pegylated IFN (PEG-IFN) may be more beneficial than non-PEG-IFN products since IFN concentration is maintained in the body at a high level, which is favorable for its action as a direct anticancer agent. (6) It may be concluded that IFN treatment after curative treatment of HCC is beneficial at least in HCV-related HCC, since it lowers recurrence and improves survival.

show abstract

Long-term course of interferon-treated chronic hepatitis C

Cited by 79 publications

References 26 publications

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma

Contact Info

Product

Resources

About